VIRGINIA M. HERNANDEZ COVINGTON, District Judge.
This matter comes before the Court pursuant to the jurisdictional briefs filed by the parties, including Plaintiff Angela Downing's request for an order of remand. (Doc. ##17, 19). For the reasons that follow, having duly considered the filings of the parties, the Court remands this action to State Court pursuant to 28 U.S.C. § 1447(c) because this Court lacks subject matter jurisdiction.
Downing alleges that she was injured after being implanted with Boston Scientific's and Ethicon's pelvic mesh devices at St. Anthony's Hospital in St. Petersburg, Florida on May 5, 2010, to treat "pelvic organ prolapse and stress urinary incontinence." (Doc. #2 at ¶¶ 43-44). Downing contends that she was forced to undergo a second "corrective surgery" at Tampa General Hospital to "revise and remove Defendants' products." (
(
Downing filed a Complaint in the Thirteenth Judicial Circuit, in and for Hillsborough County, Florida on July 15, 2014, naming the following Defendants: Boston Scientific Corporation, Ethicon, Inc., Ethicon LLC, Johnson & Johnson, Jacqueline Barry, Stephen McCastlain, Selena Mitseas, Gregory Prine, Hugh Richeson, and Jay Shellhammer. (Doc. #2). Downing's Complaint asserts the following causes of action against all Defendants: (1) strict products liability — failure to warn; (2) strict products liability — design defect; (3) negligence; (4) breach of implied warranty; (5) breach of express warranty; (6) fraud by concealment; and (7) negligent infliction of emotional distress.
On September 5, 2014, Boston Scientific Corporation, Johnson & Johnson, and Ethicon LLC (hereafter, the "Corporate Defendants") removed this action to this Court, predicating the Court's exercise of subject matter jurisdiction on complete diversity of citizenship. (Doc. #1). However, the Corporate Defendants acknowledge that Downing, along with the six individually named Defendants (Barry, McCastlain, Mitseas, Prine, Richeson, and Shellhammer) are citizens of Florida. The Corporate Defendants assert that this Court may nevertheless exercise subject matter jurisdiction over this case under the doctrine of fraudulent joinder.
On September 8, 2014, this Court directed the parties to brief the Court regarding subject matter jurisdiction. (Doc. #6). The parties have submitted their respective briefs. (Doc. ##17, 19). Among other arguments, the Corporate Defendants seek an Order staying this case in its entirety pending transfer to the Judicial Panel on Multidistrict Litigation for transvaginal mesh cases.
"Federal courts are courts of limited jurisdiction [and] possess only that power authorized by Constitution and statute, which is not to be expanded by judicial decree."
In removed cases, 28 U.S.C. § 1447(c) specifies, "[i]f at any time before final judgment it appears that the district court lacks subject matter jurisdiction, the case shall be remanded." Removal statutes are strictly construed against removal.
"In a removal case alleging fraudulent joinder, the removing party has the burden of proving that either: (1) there is no possibility the plaintiff can establish a cause of action against the resident defendant; or (2) the plaintiff has fraudulently pled jurisdictional facts."
"The determination of whether a resident defendant has been fraudulently joined must be based upon the plaintiff's pleadings at the time of removal, supplemented by any affidavits and deposition transcripts submitted by the parties."
The fact that the plaintiff may not ultimately prevail against the resident defendant is of no consequence.
The Corporate Defendants have not advanced the argument that Downing has fraudulently pled jurisdictional facts. Instead, the Corporate Defendants assert that there is no possibility the Downing can establish a cause of action against the resident defendants.
As Downing argues in her jurisdictional brief, she has "alleged that misrepresentations were made by the sales representative defendants, to Plaintiff's prescribing physician . . . [which] dealt with the safety and efficacy of the product, the warnings given by the sales representatives regarding the product and the instructions on the use of the product." (Doc. #19 at 5). Downing also explains that she "named these specific sales representatives because they were responsible for marketing and selling the incontinence and pelvic organ prolapse products that Plaintiff's physician used during Plaintiff's implant surgery on May 5, 2010." (
As was the case in
Without weighing the merits of Downing's claims, the Court finds that Downing has made a possible, colorable claim under Florida law against the non-diverse Defendants. Therefore, because the Corporate Defendants have not met their burden of establishing fraudulent joinder, the Court remands the action to State Court.
Accordingly, it is